Skip to main content
. 2018 Mar 15;11:42. doi: 10.1186/s13045-018-0585-5

Fig. 5.

Fig. 5

Relative change in palpable spleen size reduction following ruxolitinib therapy at month 24 according to baseline BM characteristics